Pipeline

Mirati is developing a pipeline of novel therapeutics that directly target the genetic and immunological drivers of cancer to ultimately help improve the lives of patients with cancer.

Mirati is developing a pipeline of novel therapeutics that directly target the genetic and immunological drivers of cancer to ultimately help improve the lives of patients with cancer.

Each of our programs is based on a scientific rationale to identify and treat patients most likely to respond to Mirati’s targeted therapies. Click on each program to learn more.

Adagrasib (MRTX849)
KRAS G12C Inhibitor

Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation.

Development
Approach
Lead
Optimization
IND-Enabling
Phase 1/1b
Phase 2
Phase 3
Monotherapy
2L+NSCLC, CRC, Pancreatic, Other
Phase 2
1L NSCLC: STK11 Co-Mutation
Phase 2
2L NSCLC
Phase 3
Combination with Pembrolizumab (PD-1)
1L NSCLC
Phase 2
Combination with Cetuximab (EGFR)
2L CRC
Phase 3
POC combinations: SHP2, Pan-EGFR, CDK4/6, SOS1
2L+ NSCLC & CRC
Phase 2
MRTX1133
KRAS G12D Inhibitor

MRTX1133 is an investigational, highly selective and potent small molecule inhibitor of the KRAS G12D mutation, designed to treat patients with high unmet need.

Development
Approach
Lead
Optimization
IND-Enabling
Phase 1/1b
Phase 2
Phase 3
Monotherapy
Pancreatic, CRC, NSCLC, Other
IND-Enabling
Sitravatinib
Multi Kinase Inhibitor

Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can potentially stimulate the body’s immune response to fight cancer.

Development
Approach
Lead
Optimization
IND-Enabling
Phase 1/1b
Phase 2
Phase 3
PD-1
2/3L NSCLC (SAPPHIRE)
Phase 3
NSCLC, Bladder & Other — Mirati-Sponsored Studies / ISTs / BeiGene1
Phase 2
Discovery Programs
Development
Approach
Lead
Optimization
IND-Enabling
Phase 1/1b
Phase 2
Phase 3
Synthetic Lethal PRMT5 Inhibitor
MTAP-Deleted Cancers
Lead Optimization
RAS Signaling Modifier
Solid Tumors
Lead Optimization
Mutant KRAS Inhibitor
Solid Tumors
Lead Optimization

NSCLC: non-small cell lung cancer; CRC: colorectal cancer; HCC: hepatocellular carcinoma; RCC: renal cell carcinoma

1. BeiGene is currently running a subset of combination studies of sitravatinib + tislelizumab (their anti-PD-1) in Asia for multiple solid tumor indications including NSCLC, HCC, RCC, ovarian and gastric cancers. BeiGene has Asian commercialization rights (ex-Japan) for sitravatinib as part of our development and commercialization agreement (Jan. 2018) and is responsible for additional data disclosures. Additional data is expected in 2021.